innerbuddies gut microbiome testing

Gut Microbiome & Atopic Dermatitis in Atopic-Prone Skin

Atopic-prone skin doesn’t just react to what touches it—it also reflects what’s happening deeper inside the body. Increasing evidence links the gut microbiome to the immune signaling that drives atopic dermatitis, suggesting that the communities of microbes in your intestines can influence how easily inflammation flares, how skin barrier repair behaves, and how your immune system “learns” to respond to triggers.

In people with atopic dermatitis, studies often find shifts in gut microbial composition and function—such as reduced microbial diversity and differences in bacteria that help produce beneficial metabolites. These compounds (including short-chain fatty acids) can regulate immune balance, support intestinal barrier integrity, and reduce inflammatory pathways that also affect the skin. When gut and immune regulation fall out of sync, it may create a body-wide environment where allergic and inflammatory responses are easier to activate.

The gut–skin connection is also shaped by lifestyle factors that can alter microbiome resilience, including diet fiber intake, early-life exposures, antibiotic use, and stress. By improving gut conditions—often through higher-quality, fiber-rich nutrition and microbiome-supporting habits—you may help steer immune responses toward a calmer, more regulated state. While gut-focused strategies aren’t a replacement for dermatologic care, they can complement skin-focused approaches by addressing underlying immune and barrier mechanisms that contribute to atopic-prone skin.

Test Your Gut for Atopic Skin Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Atopic-prone skin

Atopic-prone skin involves an impaired skin barrier, heightened immune reactivity, and dryness with eczema-like flares, while gut microbiome health modulates skin outcomes through immune education and metabolite signaling. Reduced gut diversity and early-life microbial shifts can bias immune pathways toward Th2 and IgE responses (involving IL-4/IL-13 and IL-17/IL-22), contributing to itch, redness, and barrier sensitivity. Microbial metabolites, especially short-chain fatty acids such as butyrate and propionate, help support regulatory T cells and epithelial barrier integrity, implying that fiber-rich diets and a gut ecology that favors SCFA producers may reduce flare frequency over time.

Testing and interpreting gut microbiome results—such as with InnerBuddies—can reveal diversity and functional patterns that guide personalized steps. These may include dietary adjustments to nourish beneficial microbes, targeted prebiotic or probiotic strategies, and minimized unnecessary antibiotic exposure, all aimed at promoting immune balance and barrier resilience to lessen eczema-like symptoms.

  • Low beneficial taxa such as Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Akkermansia muciniphila, Bifidobacterium spp., and Bacteroides dorei reduce butyrate/SCFA production and regulatory T cell support, impairing gut and skin barrier and promoting itch and flares.
  • Elevated taxa including Staphylococcus aureus, Klebsiella spp., Escherichia coli, Clostridium perfringens, and Bacteroides fragilis group are linked to pro-inflammatory signaling and barrier disruption, fueling eczema activity.
  • Short-chain fatty acids such as butyrate and propionate are central to immune regulation and epithelial barrier integrity; increasing dietary fiber boosts SCFA-producing microbes and may reduce skin inflammation.
  • Early-life gut dysbiosis and reduced diversity shift immune tone toward allergy-related pathways (e.g., IL-4/IL-13, IL-17/IL-22), increasing atopic dermatitis risk.
  • Gut–skin cross-talk through microbial metabolites modulates epithelial signaling and inflammatory thresholds, connecting diet and antibiotics to flare intensity.
  • Microbial competition against pathogens provides colonization resistance; disruption can elevate pathogen-driven inflammation and itch.
  • Gut microbiome testing can inform personalized dietary, prebiotic/probiotic, and antibiotic-use decisions to promote beneficial functions and potentially reduce flare frequency and severity.
Test Your Gut for Atopic Skin Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Atopic dermatitis / eczema

Atopic-prone skin is characterized by an impaired skin barrier, heightened immune reactivity, and a tendency toward dryness, itch, and inflammation. This “atopic” predisposition is commonly associated with atopic dermatitis (eczema), where microbial imbalance, both on the skin and at mucosal sites, can amplify inflammatory pathways. Growing evidence suggests that the gut microbiome—through immune education, metabolic signaling, and maintenance of barrier function—may help determine whether atopic tendencies remain mild or progress to more persistent symptoms.

Research indicates that differences in gut microbial composition and reduced microbial diversity are often observed in individuals with atopic dermatitis, particularly during early life. These gut changes can influence systemic immune tone by shaping regulatory T cells, modulating cytokine profiles (such as IL-4, IL-13, IL-17, and IL-22–related pathways), and affecting IgE-related responses. In addition, gut microbes generate metabolites—especially short-chain fatty acids (SCFAs) like butyrate and propionate—that support immune balance and help reinforce epithelial barrier integrity, which may indirectly benefit the skin’s barrier and reduce inflammatory signaling.

Key mechanisms linking the gut microbiome to atopic-prone skin include: (1) immune modulation through microbial and metabolite signaling; (2) barrier cross-talk via inflammatory mediators and gut-derived signals; and (3) competition against pathogenic organisms that can perpetuate immune activation. While diet, antibiotics, mode of birth, and early-life exposures can all alter gut ecosystems, the goal is often not to “eliminate” bacteria but to promote beneficial microbial functions. Practical insights that align with current science include supporting dietary fiber intake (for SCFA production), using targeted probiotics or prebiotics when appropriate, and minimizing unnecessary antibiotic exposure—each of which may help cultivate a gut environment that supports healthier immune regulation and, over time, may contribute to improved skin comfort and resilience in atopic dermatitis.

  • Dry, rough, or itchy skin (pruritus)
  • Eczema flares with redness and inflammation (atopic dermatitis patches/plaques)
  • Intense itching, especially at night, that disrupts sleep
  • Recurrent skin rash on typical areas (e.g., flexural surfaces, face, neck)
  • Oozing, crusting, or weeping during flares (in more severe cases)
  • Skin barrier dysfunction with increased sensitivity to irritants and temperature changes
  • Frequent skin infections or inflamed bumps around eczema areas (e.g., bacterial superinfection)
Test Your Gut for Atopic Skin Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Atopic-prone skin

It’s relevant for people with atopic-prone skin—especially those who experience frequent dryness, rough texture, and itch that can flare into eczema (atopic dermatitis). This includes individuals with recurrent rash on typical areas such as the face, neck, and flexural surfaces (elbows/knees), and those whose skin barrier feels easily irritated by soaps, temperature changes, or daily environmental triggers.

It also fits people whose symptoms suggest an ongoing immune “overreactivity,” including intense itching (often worse at night), redness and inflammation during flares, and skin sensitivity that may disrupt sleep or daily comfort. If you’ve noticed patterns where flares come and go, or you have a history that suggests early-life risk for persistent eczema, the gut–skin immune link may be especially relevant to explore.

Consider it particularly if you’ve had microbial imbalance concerns—such as recurrent infections or inflamed bumps around eczema areas, or more severe episodes with oozing, crusting, or weeping. It may be relevant for those interested in evidence-aligned gut microbiome support (e.g., improving dietary fiber intake to encourage SCFA production, and using targeted prebiotics/probiotics when appropriate) to help support immune regulation and barrier integrity over time, rather than aiming to “eliminate” bacteria.

Atopic-prone skin and atopic dermatitis (eczema) are common conditions worldwide, affecting roughly 10–20% of children and about 1–3% of adults at some point in their lives. Symptoms such as dry, rough, itchy skin and recurrent eczema flares (often on flexural areas, the face, and the neck) are especially typical in childhood, where the condition often begins early and can wax and wane over time. Because atopic-prone skin reflects an underlying tendency toward barrier dysfunction and immune reactivity, many people experience milder, persistent dryness and itch even outside classic, severe eczema—contributing to a substantial overall burden.

In early life, prevalence is particularly high: epidemiologic studies commonly report that about one in five children may develop eczema, and a large share of pediatric cases start in infancy. Common symptom patterns—intense pruritus that disrupts sleep, redness/inflammation during flares, and sometimes oozing or crusting in more severe episodes—are consistent with the clinical spectrum of atopic dermatitis. Estimates vary by region and diagnostic methods, but the overall takeaway is that atopic conditions are frequent, with rates in childhood consistently higher than in adulthood.

Atopic-prone skin often co-occurs with other atopic conditions (such as allergic rhinitis and asthma) and is associated with immune pathways linked to IgE and cytokines (e.g., IL-4/IL-13 and Th17-related signals), which can help explain why itch and inflammation may recur. Clinically, many individuals report ongoing sensitivity to irritants and temperature changes, and some develop secondary infections around eczema-affected areas—particularly when barrier integrity is impaired. Together, these patterns underscore why atopic-prone skin/atopic dermatitis represents a major dermatologic condition globally, with prevalence affecting approximately 1 in 10 to 1 in 5 people depending on age group and severity.

Test Your Gut for Atopic Skin Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & Atopic Dermatitis: How Atopic-Prone Skin Is Influenced

Atopic-prone skin is closely connected to the gut microbiome because intestinal microbes help “train” the immune system and influence inflammatory signaling that can show up as eczema-like symptoms on the skin. Research in atopic dermatitis often finds lower gut microbial diversity and shifts in community composition, especially early in life. These changes can alter immune balance—affecting regulatory T cells and cytokine patterns such as IL-4, IL-13, IL-17, and IL-22–related pathways—thereby shaping itch, redness, and flare intensity. The gut also plays a role in IgE-related immune responses, which are commonly increased in atopic conditions.

Beyond immune signaling, gut bacteria produce metabolites, particularly short-chain fatty acids (SCFAs) like butyrate and propionate, that support a more regulated immune tone. SCFAs help reinforce barrier integrity and encourage epithelial resilience, which matters because atopic-prone skin often reflects broader barrier dysfunction and increased sensitivity to irritants. When SCFA production is reduced (for example, from low fiber intake or disrupted microbiota), immune regulation may weaken, making it easier for inflammatory pathways to amplify—contributing to dry, rough, itchy skin and recurring eczema flares.

Gut–skin cross-talk also involves microbial competition against pathogens that can perpetuate immune activation. Diet, antibiotics, mode of birth, and early-life exposures can shift the microbiome in ways that either promote immune calm or increase susceptibility to inflammation, which can worsen symptoms like intense pruritus (often worse at night), weeping/crusting during flares, and inflamed bumps or infections around eczema areas. Supporting beneficial microbial functions—such as increasing dietary fiber to nourish SCFA-producing bacteria and using targeted prebiotics or probiotics when appropriate—may help foster a gut environment that supports healthier immune regulation and, over time, improves skin comfort and barrier resilience.

Test Your Gut for Atopic Skin Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Atopic-prone skin

  • Immune-system “training” by gut microbes: intestinal microbial signals help shape regulatory immune tone (e.g., regulatory T cells), which can reduce or permit atopic inflammation that shows up as eczema-like skin symptoms.
  • Cytokine pathway modulation relevant to atopic dermatitis: gut dysbiosis can shift inflammatory cytokine patterns (notably IL-4/IL-13 and IL-17/IL-22-associated signaling), influencing itch, redness, and flare severity.
  • Reduced microbial diversity and altered community composition (often early in life): lower diversity and specific community shifts are associated with higher immune reactivity and increased risk of persistent atopic-prone features.
  • IgE and allergen-sensitization effects: gut microbiome changes can influence IgE-related immune responses and allergic bias, strengthening the atopic phenotype.
  • Short-chain fatty acid (SCFA) production and barrier-supportive effects: SCFAs such as butyrate/propionate promote immune regulation and support epithelial/barrier integrity; reduced SCFAs (e.g., low fiber intake or disrupted microbiota) can weaken skin barrier resilience and amplify inflammation.
  • Microbial metabolite-driven epithelial and immune crosstalk: beyond SCFAs, other bacterial metabolites can influence skin-relevant immune signaling and inflammatory thresholds, affecting dryness, roughness, and susceptibility to flares.
  • Colonization resistance against pro-inflammatory triggers: a healthier gut community can limit pathogen overgrowth/toxin-driven immune activation; dysbiosis may increase immune stress that indirectly worsens skin inflammation.
  • Diet, birth mode, and antibiotics as upstream drivers of gut-skin outcomes: these factors reshape gut microbiota and metabolite output, thereby altering immune regulation and the likelihood/intensity of atopic skin flare-ups.

Atopic-prone skin is strongly influenced by the gut microbiome because intestinal microbes help “train” the immune system. When the gut community is balanced, microbial signals encourage a more regulatory immune tone (including regulatory T-cell activity), which can keep atopic inflammation in check. In contrast, gut dysbiosis—often reflected in reduced microbial diversity and early-life shifts in community structure—can tilt immune responses toward a more allergy-prone, inflammatory state. This immune imbalance can manifest on the skin as increased itch, redness, and a tendency to flare, especially in people who already show signs of barrier dysfunction.

Gut microbiome changes also shape the cytokine pathways commonly implicated in atopic dermatitis. Dysbiosis can alter inflammatory signaling patterns, including Th2-associated cytokines such as IL-4 and IL-13, and additional atopy-relevant axes linked with IL-17/IL-22. These shifts affect how easily the skin becomes inflamed and how intense flare symptoms feel, including pruritus and the formation of inflamed, irritated patches. The gut microbiome can further influence IgE-related immune bias and allergen sensitization, which helps strengthen the overall atopic phenotype—making it more likely that environmental triggers lead to skin reactions.

A major part of the gut–skin connection is metabolite production, particularly short-chain fatty acids (SCFAs) like butyrate and propionate. SCFAs support immune regulation and help maintain epithelial/barrier integrity, so lower SCFA output—often driven by low fiber intake or disrupted microbiota—can weaken skin resilience and amplify inflammatory cascades. Beyond SCFAs, microbial metabolites can directly modulate immune thresholds and epithelial signaling, while a diverse gut community can also provide colonization resistance against pro-inflammatory triggers. Upstream factors such as diet composition, birth mode, and antibiotic exposure can alter microbiome structure and metabolite output, thereby changing the likelihood and severity of eczema-like flare patterns over time.

Test Your Gut for Atopic Skin Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In atopic-prone skin, a common microbial pattern is lower gut microbial diversity along with an early-life shift in community composition. These changes can reduce the gut’s ability to generate immune-calming signals, leading to a greater tendency toward immune dysregulation that may surface as increased itch, redness, and a higher likelihood of flare-prone, eczema-like skin behavior. Differences in the balance of beneficial versus pro-inflammatory microbial functions can be especially relevant when the gut ecosystem is repeatedly perturbed (for example by diet low in fermentable fiber or by antibiotic exposure).

Gut dysbiosis in atopic phenotypes is also often characterized by altered functional signaling that influences T-cell balance and atopy-associated cytokine patterns. Microbial communities can affect the activity of regulatory T cells and shift inflammatory axes linked with Th2 and other atopy-relevant pathways, which may contribute to heightened skin inflammation and sensitivity to triggers. In parallel, gut-immune interactions can promote a more IgE-biased immune tone, helping maintain an overall allergic tendency that can make skin reactions more intense or persistent during exposures.

A further hallmark pattern involves reduced production of microbial metabolites—particularly short-chain fatty acids (SCFAs) such as butyrate and propionate—when fiber intake is low or when microbiota composition is disrupted. SCFAs support immune tolerance and help maintain epithelial/barrier integrity, so diminished SCFA output can weaken immune regulation and decrease barrier resilience, making skin feel drier, rougher, and more flare-prone. By shaping both immune thresholds and epithelial signaling, a less functional or less diverse gut microbiome may increase the intensity of pruritus and inflammatory episodes, while a more fiber-fed, metabolically active microbiome supports “gut–skin” cross-talk that can help calm inflammation over time.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Akkermansia muciniphila
  • Bifidobacterium spp.
  • Bacteroides dorei (Bacteroides dorei group)


Elevated / overrepresented taxa

  • Staphylococcus aureus
  • Klebsiella spp.
  • Escherichia coli (E. coli)
  • Clostridium perfringens
  • Bacteroides fragilis group


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis and butyrate/propionate production (fiber fermentation; Treg support and immune tolerance)
  • Microbial bile acid metabolism and bile acid–immune signaling (FXR/TGR5 pathways influencing barrier function and inflammation)
  • Trytophan metabolism (indole derivatives that modulate aryl hydrocarbon receptor, epithelial integrity, and Th17/Treg balance)
  • Lipopolysaccharide (LPS) and endotoxin-associated inflammatory signaling (LPS biosynthesis/outer membrane components driving pro-inflammatory cytokine tone)
  • Th2/IgE-skewing immune modulation via microbial metabolites and epithelial-immune cross-talk (regulation of allergic inflammation pathways)
  • Epithelial barrier and mucus/goblet-cell support through microbial functional outputs (e.g., mucin utilization, mucus-layer maintenance)
  • Pathogen-associated virulence and nutrient acquisition pathways (e.g., Enterobacteriaceae and S. aureus-related fitness programs that promote dysbiosis and inflammation)
  • Microbial carbohydrate fermentation and utilization of fermentable substrates (rate/efficiency of saccharide metabolism shaping metabolite output and community stability)


Diversity note

In people with atopic-prone skin, studies commonly show lower gut microbial diversity, particularly when assessing early-life gut ecosystems. This reduced diversity often comes with an altered community composition, meaning the balance of microbial groups shifts away from communities that are typically better at promoting immune tolerance. Over time, repeated perturbations—such as low intake of fermentable fibers, antibiotic exposure, or other early-life factors—can further destabilize the microbial ecosystem, making inflammatory signaling more likely to dominate.

Functionally, this diversity loss is frequently linked to a decline in the gut’s immune-calming capacity. Fewer or less effective microbial populations can produce fewer regulatory signals and metabolites (notably short-chain fatty acids like butyrate and propionate), which are important for supporting T-cell balance and restraining pro-inflammatory pathways. When SCFA production drops, immune regulation may weaken and skin-barrier support can be compromised, which can make itch, redness, and flare intensity feel more pronounced.

Because gut–skin immune cross-talk depends on both microbial presence and metabolic output, diversity-reduced microbiomes are often associated with a greater tendency toward immune dysregulation. This can contribute to a more atopy-prone immune tone, including shifts that favor allergic-type responses (such as IgE-biased activity) and heightened inflammatory responsiveness to triggers—conditions that commonly manifest as eczema-like skin behavior.


Test Your Gut for Atopic Skin Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic solutions often fail for atopic-prone skin because this condition is driven by individualized gut–immune crosstalk rather than a single, uniform “microbiome problem.” Many people have lower microbial diversity and early-life shifts in community composition, but the specific deficits (e.g., which beneficial groups are missing, what inflammatory functions are overrepresented, and whether SCFA-producing capacity is truly impaired) vary widely. Without addressing these functional patterns, broad recommendations like generic “probiotics” or one-size-fits-all diets may not meaningfully increase the gut’s ability to generate immune-calming metabolites or rebalance T-cell signaling that influences itch, redness, and flare propensity.

    Additionally, generic approaches often overlook timing and context: the microbiome’s response to diet, antibiotics, mode of birth, and early exposures can determine whether immune regulation improves or whether inflammation is primed to re-escalate. Atopic phenotypes frequently show an IgE-leaning immune tone and altered cytokine signaling patterns (including Th2-associated pathways and other inflammation axes), so interventions that target only symptoms (e.g., soothing the skin) without improving upstream microbial metabolites and barrier-supporting signals may provide short-term relief but not reduce flare frequency. If SCFA production is low—commonly linked to low fermentable fiber or disrupted microbial function—then “typical” gut support may not restore the tolerance and epithelial resilience needed for more stable skin comfort.

    Finally, atopic-prone skin involves barrier dysfunction and microbial competition effects that are highly ecosystem-dependent. A generic plan may not account for whether the gut environment is hostile to beneficial functions (such as competitive exclusion of pro-inflammatory microbes) or whether the individual’s microbiome can actually convert dietary substrates into butyrate and propionate. If the intervention doesn’t match the person’s baseline diversity, functional capacity, and degree of dysbiosis, it may fail to shift immune thresholds or strengthen the barrier-related signaling that helps reduce dryness, roughness, and nighttime pruritus. In practice, this means “works for some” strategies often underperform for those whose gut–skin pathways remain dysregulated despite generic supplementation.

  • Common mistakes

    • Using one-size-fits-all probiotics without matching the person’s likely functional deficit (e.g., low SCFA-producing capacity vs. wrong taxonomic composition).
    • Focusing on symptom relief for the skin (moisturizers/anti-itch only) while ignoring upstream gut-immune signaling drivers that influence T-cell balance and itch/inflammation thresholds.
    • Prescribing generic “healthy diet” guidance without ensuring consistent fermentable fiber intake needed to restore butyrate/propionate (SCFA) production.
    • Failing to consider timing and context (early-life microbiome disruption, antibiotic exposure, mode of birth, illness stress), which can determine whether an intervention improves tolerance or re-primes inflammation.
    • Assuming increased “microbial quantity” equals improved immune regulation, when the key issue in atopic-prone skin is often microbial function (metabolites, immune-calming signaling), not just diversity alone.
    • Ignoring individual ecosystem constraints—such as whether the gut environment supports competitive exclusion of pro-inflammatory microbes or whether beneficial strains can actually convert substrates into SCFAs.
    • Changing multiple variables at once (diet, supplements, antibiotics, pre/probiotics) without tracking response, making it impossible to identify what improved or worsened gut–skin cross-talk.
    • Overlooking that flare propensity may be linked to IgE-biased immune tone and Th2-associated cytokine patterns, and using interventions that don’t target those immune-programming pathways.

What to do

  • General support strategies

    Atopic-prone skin is strongly influenced by gut–immune communication, so general support strategies focus on creating a microbiome that supports immune balance and reduces inflammatory “set points.” Research in atopic dermatitis commonly shows reduced gut microbial diversity and shifts in community structure, particularly early in life; these patterns can affect how regulatory immune pathways develop, influencing cytokine networks involved in itch and flare activity (including IL-4/IL-13 and broader Th2/Th17–related signaling). Supporting a gut environment that promotes immune tolerance—while avoiding unnecessary microbiome disruption (e.g., frequent or prolonged antibiotic exposure when not medically indicated)—can be an important foundation for improving skin comfort over time.

    Diet is one of the most actionable levers for microbiome function. Increasing fiber intake helps nourish short-chain fatty acid (SCFA)-producing bacteria that generate metabolites like butyrate and propionate, which help reinforce immune regulation and support barrier integrity. When SCFA production is robust, epithelial resilience and inflammatory restraint tend to improve, which can translate to less dryness, reduced reactivity to irritants, and fewer or less intense eczema flares. Emphasizing a variety of plant-based foods (including prebiotic fibers from vegetables, legumes, oats, and other whole grains) can also improve microbial diversity and metabolic output.

    Where diet alone is insufficient, targeted probiotic or prebiotic approaches may help shift the microbiome toward more protective functions, such as competitive exclusion of potential pathogen overgrowth and enhanced regulation of inflammatory signaling. Because individual microbiome responses vary, it’s reasonable to choose interventions thoughtfully and monitor skin changes rather than expecting immediate results. Overall, consistent support of a fiber-rich, minimally disruptive gut environment—optionally complemented with evidence-informed probiotic or prebiotic strategies when appropriate—offers a practical route to supporting immune calm, healthier skin barrier behavior, and improved day-to-day itch and flare control.

  • Lifestyle recommendations

    • Increase dietary fiber (e.g., beans/lentils, oats, vegetables, fruits) to support SCFA-producing gut bacteria and stronger immune regulation.
    • Prioritize a diverse, minimally processed whole-food diet (varied plants/fermented foods if tolerated) to enhance gut microbial diversity.
    • Avoid unnecessary antibiotics and reduce other major microbiome disruptors when possible; discuss any needed antibiotics with a clinician (timing and possible probiotic support).
    • If appropriate, consider targeted probiotics or prebiotics (from food or supplements) after discussing with a healthcare professional—especially in infants/children or if symptoms are persistent.
    • Support gut–skin barrier health with adequate hydration and consistent gentle skin-care routines (and manage triggers like irritant soaps/wool/fragrances), since barrier dysfunction can amplify flares.
    • Identify and limit food or environmental triggers that worsen eczema for you/your child (common ones include certain allergens, dry air, overheating/sweating), using a symptom diary.

  • Nutrition recommendations

    • Increase dietary fiber (aim for a variety of plant foods: legumes, oats, whole grains, berries, vegetables) to support SCFA-producing gut bacteria (e.g., butyrate/propionate).
    • Prioritize a “microbiome-friendly” diet pattern rich in diverse plants and minimally processed foods; include prebiotic fibers like inulin/FOS, chicory root, garlic, leeks, asparagus, and beans as tolerated.
    • Include omega-3 fats regularly (fatty fish such as salmon/sardines or algae-based DHA/EPA) to help modulate inflammatory signaling associated with atopic flares.
    • Support gut barrier and immune balance with fermented foods if tolerated (e.g., yogurt/kefir with live cultures, sauerkraut, kimchi), starting small to assess for tolerance.
    • Limit ultra-processed foods and added sugars, as they can worsen gut microbial balance and may increase inflammatory tone linked to eczema activity.
    • Consider probiotic or targeted prebiotic supplementation only if appropriate (e.g., strains studied for eczema/immune modulation), ideally alongside dietary fiber rather than as a replacement.

  • Supplement considerations

    For atopic-prone skin, supplement strategies often focus on supporting gut microbial diversity and the immune “training” that helps keep inflammatory signaling in check. Because research in atopic dermatitis commonly shows altered early-life microbiome patterns, options that promote a healthier microbial ecosystem (for example, targeted probiotics or prebiotic fibers) may help encourage a more balanced immune tone. This includes pathways tied to T-cell regulation and cytokines involved in atopic inflammation (such as IL-4/IL-13 and other skin-relevant immune signals), which can influence itch, redness, and flare tendency.

    A key rationale is that gut bacteria generate metabolites—especially short-chain fatty acids (SCFAs) like butyrate and propionate—that support barrier integrity and immune regulation. Supplements that increase SCFA availability (commonly via prebiotic fibers or substrates that beneficial bacteria use) may help reinforce epithelial resilience and potentially reduce the “reactivity” that drives dry, rough, itchy skin. In practice, the goal is less about a quick symptom switch and more about gradually improving the gut conditions that support regulated immune responses and a stronger skin barrier phenotype.

    Because gut–skin cross-talk also involves controlling inflammatory amplification and microbial competition, the timing and context of supplementation matter. Antibiotic use, mode of birth, and diet patterns can shift microbial communities, so interventions may be most helpful when started consistently for a defined trial period (often several weeks) while also addressing dietary drivers like fiber intake. If choosing probiotics, select strains with human evidence for atopic or eczema-relevant outcomes and consider individualized tolerance; in sensitive individuals, starting low and monitoring skin and GI responses can be important. For those with frequent flares, weeping, or recurrent infections, working with a clinician is advisable to ensure supplements complement—rather than replace—core skin and medical management.

  • Retesting / monitoring note

    For atopic-prone skin, retesting is often most informative when it targets gut–immune markers and gut microbial function rather than relying on a single snapshot. If an initial microbiome assessment shows low microbial diversity or an inflammatory-leaning community profile, consider retesting after a defined intervention window (commonly 8–12 weeks) to allow time for diet-derived substrates to shift microbial activity and for immune signaling patterns to stabilize. This is especially relevant because early-life and ongoing environmental exposures can influence microbial composition and cytokine balance—pathways associated with itch, redness, and flare intensity (e.g., IL-4/IL-13 and IL-22-related signaling).

    Retesting is most valuable when paired with consistent pre-test conditions: avoid major changes in fiber intake, diet pattern, antibiotic/probiotic use, or medication timing right before testing. If antibiotics were used recently, a longer washout period (often 4–8+ weeks, depending on the specific antibiotic and clinician guidance) may be needed before retesting to reduce false conclusions about baseline microbiology. For interventions aimed at supporting SCFA-producing bacteria (e.g., increased fermentable fiber or targeted pre-/probiotics), retesting can help confirm that gut fermentation capacity is improving—since higher SCFA output (such as butyrate and propionate) is linked to better immune regulation and barrier resilience, both of which can influence eczema-like symptoms.

    Finally, consider retesting in a way that reflects real-world symptom cycles. Because atopic flares can be periodic, testing during relatively stable periods (or repeating across two phases: stable vs. flare onset) can clarify whether microbial shifts precede symptom changes or merely accompany them. Tracking outcomes—such as itch severity, dryness/roughness, and flare frequency alongside test results—helps determine whether microbiome changes correlate with improved immune tone and reduced inflammation-driven skin reactivity.

The importance of gut microbiome testing

  • Why testing matters

    For atopic-prone skin, gut microbiome testing matters because it can reveal whether the intestinal microbial diversity and community composition are shifted in ways that commonly associate with atopic dermatitis–type inflammation. Since gut microbes help “train” the immune system and influence inflammatory signaling, testing can identify patterns (such as reduced diversity or altered balance among key microbial groups) that may correlate with immune imbalance. That imbalance can affect cytokine pathways involved in itch and redness (including IL-4/IL-13–related responses and other immune circuits like IL-17/IL-22–associated signaling), helping explain why some people are more prone to flares.

    Testing can also inform whether the microbiome is likely supporting protective metabolite production—especially short-chain fatty acids (SCFAs) like butyrate and propionate. These metabolites support immune regulation and help maintain epithelial/barrier resilience, which is relevant because atopic-prone skin often involves barrier dysfunction and heightened sensitivity to irritants. A test may point to reduced “beneficial function” signals that could stem from low fiber intake, disrupted microbial ecology, or recent antibiotic exposure, giving you a more targeted rationale for dietary or lifestyle adjustments rather than relying on guesswork.

    Finally, gut microbiome results can help connect gut–skin cross-talk to real-world drivers such as diet, early-life exposures, and medication history (for example, antibiotics or birth mode). By seeing how microbial communities and functional markers look for your body, you can better choose next steps—like targeted prebiotic fiber strategies, probiotic considerations, and anti-inflammatory dietary patterns—aimed at promoting microbial stability and immune calm. In turn, that may support fewer or less intense inflammatory skin episodes and improved skin comfort over time.

  • How InnerBuddies helps

    InnerBuddies can help with atopic-prone skin by assessing gut microbiome patterns linked to immune “training” and inflammatory balance. Since research associates atopic dermatitis–type inflammation with lower microbial diversity and shifts in community composition—especially early in life—your results can show whether your gut ecology reflects a less resilient, more pro-inflammation-prone state. This matters because gut microbes influence cytokine signaling involved in itch, redness, and flare intensity (including IL-4/IL-13 pathways and related immune circuits).

    Beyond composition, the InnerBuddies test can provide insight into whether your gut environment is likely supporting protective microbial functions, including the production of short-chain fatty acids (SCFAs) such as butyrate and propionate. These metabolites help support immune regulation and reinforce epithelial/barrier integrity, both of which are relevant when atopic-prone skin is prone to dryness, rough texture, and barrier dysfunction. When SCFA-supporting activity is reduced—often influenced by factors like lower fiber intake or microbiome disruption—immune tone may become less controlled, making skin more reactive.

    Finally, by connecting your gut findings to real-world drivers (for example, diet habits, antibiotic history, and early-life exposures that can shift microbiome stability), InnerBuddies helps move from guesswork to a more personalized plan. The results can guide more targeted next steps—such as diet adjustments that nourish beneficial microbes or considerations around prebiotic and probiotic strategies—to promote microbial balance and immune calm over time, with the goal of improving skin comfort and reducing the frequency or intensity of flare-like symptoms.

Medical Evidence

  • Scientific evidence level

    3 [Moderate: microbiome–atopic skin links are plausible and repeatedly observed, but causality and clinically actionable utility remain unproven.]

  • Clinical relevance note

    What would “actionable” mean here? For atopic-prone skin, an actionable clinical use would require (1) a reproducible microbiome feature set tied to risk or phenotype, (2) demonstration that using that information improves outcomes (e.g., better prevention strategy selection, targeted therapy selection, or improved monitoring), and (3) evidence that microbiome-targeted interventions improve those outcomes. As of now, none of these steps are sufficiently validated across diverse cohorts.

    In current clinical relevance, gut microbiome findings should be viewed as hypothesis-generating to moderately informative for research risk stratification, not as a basis for diagnosis or management. Microbiome-modulating approaches (probiotics/prebiotics) are not uniformly supported to prevent or treat atopic dermatitis across populations; heterogeneity in interventions and endpoints limits conclusions. Consequently, the scientific evidence supports that the gut–skin axis is biologically plausible and that dysbiosis-like patterns are associated with atopic dermatitis risk and presence, but causality and clinical implementation remain unproven. The uncertainty is largely driven by confounding (diet, antibiotics, medications, delivery mode), reverse causality (eczema inflammation/medication changing gut microbiome), methodological inconsistency (batch effects, pipeline differences), and limited external validation of any predictive models.

Title Journal Year Link
Gut microbiota in atopic dermatitis—A systematic review and meta-analysis of human studies Journal of Dermatological Science 2021 View →
Microbiome and atopic dermatitis: A systematic review and meta-analysis Frontiers in Immunology 2020 View →
Skin barrier dysfunction links to gut microbiome alterations in atopic dermatitis Cell Reports 2018 View →
Maternal gut microbiota and atopic dermatitis in offspring: A prospective birth cohort study Gut 2017 View →
The gut microbiome of patients with atopic dermatitis and their relationship with SCORAD and IgE levels Scientific Reports 2015 View →

Frequently Asked Questions

    Qu'est-ce que la peau à tendance atopique?
    C’est une propension à une peau sèche et qui démange, avec une barrière cutanée perturbée et une réactivité immunitaire accrue, souvent liée à l’eczéma (dermatite atopique).
    Comment le microbiome intestinal influence-t-il la peau en cas d’atopie?
    Les microbes intestinaux aident à « entraîner » le système immunitaire et influencent les signaux inflammatoires et les réactions cutanées, notamment via les SCFA qui soutiennent la barrière.
    Qu'est-ce que les acides gras à chaîne courte (SCFA) et pourquoi sont-ils importants?
    Les SCFA (par ex. le butyrate et le propionate) sont des métabolites produits par les bactéries intestinales lors de la fermentation des fibres; ils soutiennent l’équilibre immunitaire et l’intégrité de la barrière.
    Quels microbes intestinaux sont généralement plus faibles ou plus élevés dans l’atopie?
    Plus faibles: Faecalibacterium prausnitzii, Roseburia, Eubacterium rectale, Akkermansia muciniphila, Bifidobacterium, Bacteroides dorei. Plus élevés: Staphylococcus aureus, Klebsiella, Escherichia coli, Clostridium perfringens, groupe Bacteroides fragilis.
    Le régime peut-il influencer le microbiome et la peau?
    Oui. Une alimentation riche en fibres favorise la production de SCFA et peut soutenir la régulation immunitaire et l’inflammation cutanée.
    Dois-je prendre des probiotiques ou des prébiotiques pour la peau atopique?
    Ils peuvent aider dans certains cas, mais cela doit être guidé par des preuves et une recommandation professionnelle; ce n’est pas une solution universelle.
    Comment les antibiotiques affectent-ils la connexion intestin–peau?
    Les antibiotiques peuvent perturber la diversité du microbiote et la production de métabolites, ce qui peut influencer l’équilibre immunitaire et les poussées cutanées.
    Quel est le rôle de l’immunoglobuline E (IgE) et des cytokines comme IL-4/IL-13 dans la peau atopique?
    IgE et les cytokines Th2 favorisent l’inflammation allergique et les démangeaisons; d’autres voies comme IL-17/IL-22 peuvent aussi être impliquées.
    Quelles preuves soutiennent la connexion intestin–peau dès la petite enfance?
    Des changements précoces du microbiome intestinal sont souvent observés dans l’eczéma infantile et peuvent influencer le développement immunitaire et l’inflammation.
    Que peut révéler un test du microbiome intestinal?
    Il peut montrer la diversité et des signaux fonctionnels (par ex. le potentiel de production de SCFA) utiles pour guider des choix de mode de vie.
    Comment soutenir la santé intestinale pour aider la peau?
    Privilégier les aliments riches en fibres, éviter les antibiotiques non nécessaires et envisager des approches pré-/probiotiques ciblées selon les conseils médicaux.
    Quels symptômes doivent amener à consulter?
    Infections sévères, démangeaisons intenses ou persistantes, plaques rouges et inflammées avec écoulement ou croûtes, fièvre.
    À quel point la peau à tendance atopique est-elle fréquente?
    Très fréquente dans le monde; environ 10–20% des enfants et 1–3% des adultes à différents stades.
    Qu’est-ce que InnerBuddies et comment cela s’y rapporte?
    Une évaluation du microbiome intestinal qui aide à comprendre l’entraînement immunitaire et les fonctions liées aux SCFA pour guider les choix diététiques et le mode de vie.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -